A Phase 3 interventional study of Oral Budesonide Suspension (OBS) and Placebo in Eosinophilic Esophagitis (EoE), sponsored by Shire. Completed at 77 sites in United States. Open to participants aged 11 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.
Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one has the largest enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 12th registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 11 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 7 · Phase 4 3
First in 2005; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 318 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 79 across the 18 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 5 studies filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
1 of the studies testing budesonide in Eosinophilic Esophagitis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596252Phase 3Dr. Falk Pharma GmbHOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing budesonide in Eosinophilic Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
Drug: Oral Budesonide Suspension (OBS)
Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
Drug: Placebo
Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
Oral dose of 10 ml of placebo matched with the experimental drug.
Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16)
Histologic response was defined as a peak eosinophil count of less than or equal to (\<=) 6/ high-powered field (HPF) across all available esophageal levels at final treatment period evaluation (Week 16). Histologic response after 12 weeks of double blind treatment at Week 16 was reported.
Time frame: Week 16
Number of Participants With Dysphagia Symptom Response at the Final Treatment Period Evaluation (Week 16)
Dysphagia symptom response was defined as greater than or equal to (\>=) 30 percent (%) reduction in the Dysphagia Symptom Questionnaire (DSQ) combined score (questions 2+3). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Dysphagia symptom response after 12 weeks of double blind treatment at Week 16 was reported.
Time frame: Week 16
Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Combined Score at the Final Treatment Period Evaluation (Week 16)
DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ combined score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2 and 0 - 4 for question 3, with higher values representing a worse outcome. Scale range for DSQ combined score was 0 - 84, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ after 12 weeks of double blind treatment at Week 16 was reported.
Time frame: Baseline, Week 16
Change From Baseline in Total Endoscopy Score at the Final Treatment Period Evaluation (Week 16)
Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 categories: 1) exudates or plaques (grade 0-2); 2) fixed esophageal rings (grade 0-3); 3) edema (grade 0-2); 4) furrows (grade 0-2); and 5) strictures (grade 0-1). An endoscopy score for each category was calculated and summed for each anatomic location (proximal and distal). The minimum and maximum endoscopy score was 0 and 10 points respectively for each location (proximal and distal) and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points respectively). The higher score indicated worse appearance. A negative change from baseline indicates that appearance improved. Endoscopic findings after 12 weeks of double blind treatment at Week 16 were reported.
Time frame: Baseline, Week 16
Number of Participants With Peak Eosinophil Count Less Than (<)15/High-Powered Field (HPF) or Less Than or Equal to (<=)1/High-Powered Field (HPF) at the Final Treatment Period Evaluation (Week 16)
Participant was considered as responder at Week 16 if he/she had peak eosinophil count of \<15/HPF or \<=1/HPF across all esophagus levels. Number of participants with peak eosinophil count \< 15/HPF or \<=1/HPF after 12 weeks of double blind treatment at Week 16 were reported.
Time frame: Week 16
Change From Baseline in the Peak Eosinophil Count at the Final Treatment Period Evaluation (Week 16)
Change from baseline in the peak eosinophil count after 12 weeks of double blind treatment at week 16 for each available esophageal level (proximal, mid, distal, maximum) were reported.
Time frame: Baseline, Week 16
Change From Baseline in the Histopathologic Epithelial Features Combined Total Score Ratio (TSR) at the Final Treatment Period Evaluation (Week 16)
Change from baseline in histopathologic epithelial features combined total score of grade and stage ratio after 12 weeks of double blind treatment at Week 16 were reported by measuring eight histopathologic epithelial features: basal layer hyperplasia, eosinophil density, eosinophil micro-abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, lamina propria fibrosis were scored on a 4-point scale (0=normal, 3=worst) for both the severity of the abnormality (grade) and the amount of tissue affected by the abnormality (stage). Thus each of the 3 levels had a minimum score of 0 and maximum possible score of 24, and a possible total grade or stage score of 72 for a maximum combined score of 144. Combined total score ratio (TSR) =(proximal TSR + mid TSR + distal TSR)/N, where N is the number of non missing sections for TSR. A negative change from baseline indicates that epithelial inflammation decreased.
Time frame: Baseline, Week 16
Number of Participants With Dysphagia Symptom Response (Binary Response) at the Final Treatment Period Evaluation (Week 16)
Dysphagia symptom response (binary response \[i.e, responders versus. non-responders\]) was defined as a \>=50% reduction in the DSQ combined score (questions 2+3), from baseline to the final treatment period evaluation (Week 16). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Number of participants with binary response after 12 weeks of double blind treatment at Week 16 were reported.
Time frame: Week 16
Number of Participants With Overall Binary Response I at the Final Treatment Period Evaluation (Week 16)
Overall binary response I was defined as a reduction in the DSQ score of \>=30% from baseline to the final treatment period (week 16) evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 30% reduction in DSQ combined score between baseline and Week 16 and has peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response I after 12 weeks of double blind treatment at Week 16 were reported.
Time frame: Week 16
Number of Participants With Overall Binary Response II at the Final Treatment Period Evaluation (Week 16)
Overall binary response II was defined as a reduction in the DSQ score of \>=50% from baseline to the final treatment period evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 50% reduction in DSQ combined score between baseline and Week 16 and had peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response II after 12 weeks of double blind treatment at Week 16 were reported.
Time frame: Week 16
Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) + Pain Score (Questions 2 +3+4) at the Final Treatment Period Evaluation (Week 16)
DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ + pain score was calculated by summing the scores of responses to questions 2, 3, and 4 by using following formula: DSQ + pain score= (\[sum of points from questions 2+3+4 in the daily DSQ\] ×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2, 0 - 4 for question 3 and 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ + pain score was 0 - 140, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased.
Time frame: Baseline, Week 16
Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) Pain Score (Question 4) at the Final Treatment Period Evaluation (Week 16)
DSQ pain score was calculated by summing the scores of responses to Question 4 (extent to which the participant experienced pain while swallowing) only, by using the following formula: DSQ pain score= \[(sum of points from question 4 in the daily DSQ)×14\]/ Number of diaries reported with non-missing data. Scale range was 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ pain score was 0 - 56, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ pain score (question 4) after 12 weeks of double blind treatment at Week 16 were reported.
Time frame: Baseline, Week 16
Number of Participants With Treatment-Emergent Adverse Events (AE)
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that start or deteriorate on or after the first dose of double-blind IP (Week 44) and through the safety follow-up contact, or 31 days after the last dose of IP for participants who did not have a safety follow-up contact. Number of participants with TEAE's were reported.
Time frame: From start of study drug administration up to follow-up (Week 20)
Area Under the Plasma Concentration-Time Curve (AUCtau) Between the Defined Interval of Budesonide Doses
Area under the curve for the defined interval between doses (12 hours), calculated using the linear-up/log-down trapezoidal rule.The AUCtau of plasma budesonide was reported. Hours times pico grams per milliliter was abbreviated as h.pg/mL.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Maximum Observed Concentration (Cmax) of Budesonide in Plasma
The Cmax of budesonide in plasma was reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Time to Maximum Observed Plasma Concentration (Tmax) of Budesonide in Plasma
Tmax of budesonide in plasma was reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Terminal Rate Constant (Lambda Z) of Budesonide in Plasma
Lambda Z of budesonide in plasma was reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Terminal Half-Life (t1/2) of Budesonide in Plasma
t1/2 of budesonide in plasma was reported
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Apparent Oral Clearance (CL/F) of Budesonide in Plasma
CL/F of budesonide in plasma was reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Apparent Volume of Distribution (Vz/F) of Budesonide in Plasma
Vz/F of budesonide in plasma was reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
This study was conducted at 72 sites in North America from 07 December 2015 (first participant enrolled) to 15 February 2019 (last participant completed).
| Milestone | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Started | 105 | 213 |
| Completed | 94 | 202 |
| Not completed | 11 | 11 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 8 |
| Withdrew: Physician decision | 0 | 1 |
Histologic response was defined as a peak eosinophil count of less than or equal to (\<=) 6/ high-powered field (HPF) across all available esophageal levels at final treatment period evaluation (Week 16). Histologic response after 12 weeks of double blind treatment at Week 16 was reported.
| Participants | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Histology Response - Yes | 1 | 113 |
| Histology Response - No | 104 | 100 |
Dysphagia symptom response was defined as greater than or equal to (\>=) 30 percent (%) reduction in the Dysphagia Symptom Questionnaire (DSQ) combined score (questions 2+3). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Dysphagia symptom response after 12 weeks of double blind treatment at Week 16 was reported.
| Participants | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Dysphagia symptom response: Yes | 41 | 112 |
| Dysphagia symptom response: No | 64 | 101 |
DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ combined score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2 and 0 - 4 for question 3, with higher values representing a worse outcome. Scale range for DSQ combined score was 0 - 84, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ after 12 weeks of double blind treatment at Week 16 was reported.
| Score on scale | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Combined Score at the Final Treatment Period Evaluation (Week 16) | -9.07 ± 1.519 | -12.99 ± 1.202 |
Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 categories: 1) exudates or plaques (grade 0-2); 2) fixed esophageal rings (grade 0-3); 3) edema (grade 0-2); 4) furrows (grade 0-2); and 5) strictures (grade 0-1). An endoscopy score for each category was calculated and summed for each anatomic location (proximal and distal). The minimum and maximum endoscopy score was 0 and 10 points respectively for each location (proximal and distal) and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points respectively). The higher score indicated worse appearance. A negative change from baseline indicates that appearance improved. Endoscopic findings after 12 weeks of double blind treatment at Week 16 were reported.
| score on scale | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Change From Baseline in Total Endoscopy Score at the Final Treatment Period Evaluation (Week 16) | -2.2 ± 0.38 | -4.0 ± 0.30 |
Participant was considered as responder at Week 16 if he/she had peak eosinophil count of \<15/HPF or \<=1/HPF across all esophagus levels. Number of participants with peak eosinophil count \< 15/HPF or \<=1/HPF after 12 weeks of double blind treatment at Week 16 were reported.
| Participants | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Peak Eosinophil Count (<15/HPF): Responders | 1 | 132 |
| Peak Eosinophil Count (<15/HPF): Non-responders | 104 | 81 |
| Peak Eosinophil Count (<=1/HPF): Responders | 0 | 69 |
| Peak Eosinophil Count (<=1/HPF): Non-responders | 105 | 144 |
Change from baseline in the peak eosinophil count after 12 weeks of double blind treatment at week 16 for each available esophageal level (proximal, mid, distal, maximum) were reported.
| eosinophil count | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Proximal: Week 16 | -5.5 ± 3.19 | -34.0 ± 2.52 |
| Mid: week 16 | -12.9 ± 3.74 | -43.3 ± 3.01 |
| Distal: Week 16 | -4.9 ± 3.66 | -38.0 ± 2.88 |
| Maximum: Week 16 | -7.6 ± 4.27 | -55.2 ± 3.37 |
Change from baseline in histopathologic epithelial features combined total score of grade and stage ratio after 12 weeks of double blind treatment at Week 16 were reported by measuring eight histopathologic epithelial features: basal layer hyperplasia, eosinophil density, eosinophil micro-abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, lamina propria fibrosis were scored on a 4-point scale (0=normal, 3=worst) for both the severity of the abnormality (grade) and the amount of tissue affected by the abnormality (stage). Thus each of the 3 levels had a minimum score of 0 and maximum possible score of 24, and a possible total grade or stage score of 72 for a maximum combined score of 144. Combined total score ratio (TSR) =(proximal TSR + mid TSR + distal TSR)/N, where N is the number of non missing sections for TSR. A negative change from baseline indicates that epithelial inflammation decreased.
| score on scale | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Grade - Combined TSR: Week 16 | -0.03 ± 0.016 | -0.22 ± 0.013 |
| Stage - Combined TSR: Week 16 | -0.0 ± 0.02 | -0.2 ± 0.01 |
Dysphagia symptom response (binary response \[i.e, responders versus. non-responders\]) was defined as a \>=50% reduction in the DSQ combined score (questions 2+3), from baseline to the final treatment period evaluation (Week 16). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Number of participants with binary response after 12 weeks of double blind treatment at Week 16 were reported.
| Participants | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Responders | 35 | 88 |
| Non Responders | 70 | 125 |
Overall binary response I was defined as a reduction in the DSQ score of \>=30% from baseline to the final treatment period (week 16) evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 30% reduction in DSQ combined score between baseline and Week 16 and has peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response I after 12 weeks of double blind treatment at Week 16 were reported.
| Participants | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Overall Binary Response I: Responders | 0 | 64 |
| Overall Binary Response I: Non Responders | 105 | 149 |
Overall binary response II was defined as a reduction in the DSQ score of \>=50% from baseline to the final treatment period evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 50% reduction in DSQ combined score between baseline and Week 16 and had peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response II after 12 weeks of double blind treatment at Week 16 were reported.
| Participants | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Overall binary response II: Responders | 0 | 48 |
| Overall binary response II: Non-Responders | 105 | 165 |
DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ + pain score was calculated by summing the scores of responses to questions 2, 3, and 4 by using following formula: DSQ + pain score= (\[sum of points from questions 2+3+4 in the daily DSQ\] ×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2, 0 - 4 for question 3 and 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ + pain score was 0 - 140, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased.
| Score on scale | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) + Pain Score (Questions 2 +3+4) at the Final Treatment Period Evaluation (Week 16) | -12.24 ± 2.097 | -18.65 ± 1.660 |
DSQ pain score was calculated by summing the scores of responses to Question 4 (extent to which the participant experienced pain while swallowing) only, by using the following formula: DSQ pain score= \[(sum of points from question 4 in the daily DSQ)×14\]/ Number of diaries reported with non-missing data. Scale range was 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ pain score was 0 - 56, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ pain score (question 4) after 12 weeks of double blind treatment at Week 16 were reported.
| score on scale | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) Pain Score (Question 4) at the Final Treatment Period Evaluation (Week 16) | -3.01 ± 0.751 | -5.47 ± 0.595 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that start or deteriorate on or after the first dose of double-blind IP (Week 44) and through the safety follow-up contact, or 31 days after the last dose of IP for participants who did not have a safety follow-up contact. Number of participants with TEAE's were reported.
| Participants | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AE) | 64 | 130 |
Area under the curve for the defined interval between doses (12 hours), calculated using the linear-up/log-down trapezoidal rule.The AUCtau of plasma budesonide was reported. Hours times pico grams per milliliter was abbreviated as h.pg/mL.
| h.pg/mL | Oral Budesonide Suspension (OBS) |
|---|---|
| Area Under the Plasma Concentration-Time Curve (AUCtau) Between the Defined Interval of Budesonide Doses | 5071 ± 58.1 |
The Cmax of budesonide in plasma was reported.
| Picograms per milliliter (pg/mL) | Oral Budesonide Suspension (OBS) |
|---|---|
| Maximum Observed Concentration (Cmax) of Budesonide in Plasma | 914.8 ± 59.2 |
Tmax of budesonide in plasma was reported.
| hour | Oral Budesonide Suspension (OBS) |
|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Budesonide in Plasma | 2 (0.50 to 4) |
Lambda Z of budesonide in plasma was reported.
| per hour | Oral Budesonide Suspension (OBS) |
|---|---|
| Terminal Rate Constant (Lambda Z) of Budesonide in Plasma | 0.2103 ± 25.2 |
t1/2 of budesonide in plasma was reported
| hour | Oral Budesonide Suspension (OBS) |
|---|---|
| Terminal Half-Life (t1/2) of Budesonide in Plasma | 3.296 ± 25.2 |
CL/F of budesonide in plasma was reported.
| Liter per hour (L/h) | Oral Budesonide Suspension (OBS) |
|---|---|
| Apparent Oral Clearance (CL/F) of Budesonide in Plasma | 394.4 ± 58.1 |
Vz/F of budesonide in plasma was reported.
| Liter (L) | Oral Budesonide Suspension (OBS) |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Budesonide in Plasma | 1886 ± 51.4 |
Collected over From start of study drug administration up to follow-up (Week 20). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/105 (0%) | 1/105 (1%) | 28/105 (26.7%) |
| Oral Budesonide Suspension (OBS) | 0/213 (0%) | 2/213 (0.9%) | 63/213 (29.6%) |
| Event | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| Ovarian cystReproductive system and breast disorders | 1/105 | 0/213 |
| Localised intraabdominal fluid collectionGastrointestinal disorders | 0/105 | 1/213 |
| GastroenteritisInfections and infestations | 0/105 | 1/213 |
| SepsisInfections and infestations | 0/105 | 1/213 |
| Event | Placebo | Oral Budesonide Suspension (OBS) |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/105 | 11/213 |
| DiarrhoeaGastrointestinal disorders | 5/105 | 2/213 |
| SinusitisInfections and infestations | 3/105 | 9/213 |
| VomitingGastrointestinal disorders | 4/105 | 4/213 |
| Mood swingsPsychiatric disorders | 4/105 | 3/213 |
| Oesophageal candidiasisInfections and infestations | 2/105 | 8/213 |
| Oral candidiasisInfections and infestations | 0/105 | 8/213 |
| HeadacheNervous system disorders | 1/105 | 7/213 |
| NauseaGastrointestinal disorders | 3/105 | 6/213 |
| Upper respiratory tract infectionInfections and infestations | 3/105 | 4/213 |
Full analysis set (FAS) included all randomized participants who received at least one dose of a double-blind investigational product (IP).
| Age, Continuous(Years) | Placebo | Oral Budesonide Suspension (OBS) | Total |
|---|---|---|---|
| Mean | 33.9 ± 12.13 | 33.8 ± 11.89 | 33.9 ± 11.95 |
| Sex: Female, Male(Participants) | Placebo | Oral Budesonide Suspension (OBS) | Total |
|---|---|---|---|
| Female | 43 | 84 | 127 |
| Male | 62 | 129 | 191 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Oral Budesonide Suspension (OBS) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 8 | 10 |
| Not Hispanic or Latino | 100 | 204 | 304 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Placebo | Oral Budesonide Suspension (OBS) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 5 | 5 |
| White | 101 | 200 | 301 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 7 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.
Ran from Dec 2015 to primary completion in Jan 2019, 37 months.
Results were first posted in Mar 2020, 1 year 1 month after primary completion.
Of 16 phase 3 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide